x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012191
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP, IF |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence of human IRAP protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | LNPEP |
| UniProt No. | Q9UIQ6 |
| Gene ID | 4012 |
| Gene Description | IRAP was originally described as an insulin-responsive aminopeptidase found in Glut4-containing vesicles. It is essentially always in the same compartments as Glut4 and has identical insulin-stimulated translocation patterns as Glut4. IRAP is therefore considered to be a surrogate marker for Glut4. IRAP was later found to be a critical enzyme that regulates the expression and activity of several essential hormones and regulatory proteins, including the Glut4 transporter. This membrane associated, zinc-dependent cystinyl aminopeptidase acts as both a receptor for angiotensin IV as well as the enzyme that catalyzes the synthesis of this essential hormone from its angiotensinogen precursor. IRAP catalyzes the hydrolysis of several peptide hormones, including oxytocin and vasopressin. Abnormal IRAP expression or activity is associated with several forms of cancer in humans, including renal and endometrial cancers. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
